Lungenbeteiligung bei systemischer Sklerodermie

H. Knoop; U. Arinir; A. Kreuter; J. W. Walther; G. Schultze-Werninghaus; G. Rohde

doi:10.1055/s-0029-1214908

Pneumologie 2009; 63(9): 497-507
DOI: 10.1055/s-0029-1214908

Übersicht

Lungenbeteiligung bei systemischer Sklerodermie

Lung Impairment in Systemic SclerosisH. Knoop¹ , U. Arinir¹ , A. Kreuter² , J. W. Walther¹ , G. Schultze-Werninghaus¹ , G. Rohde¹

¹Medizinische Klinik III – Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin, Berufsgenossenschaftliche Universitätsklinik Bergmannsheil GmbH, Klinikum der Ruhr-Universität Bochum (Direktor: Prof. Dr. G. Schultze-Werninghaus)
²Klinik für Dermatologie und Allergologie, St. Josef-Hospital, Klinikum der Ruhr-Universität Bochum (Direktor: Prof. Dr. P. Altmeyer)

Abstract

Zusammenfassung

Unter dem Oberbegriff Sklerodermie werden heterogene Autoimmunerkrankungen zusammengefasst, die verdickte, sklerotische Hautläsionen gemein haben. Die Sklerodermie zählt zum Formenkreis der Kollagenosen. Die systemische Form der Sklerodermie wird als Progressive Systemische Sklerose (PSS) oder systemische Sklerodermie (SSc) bezeichnet. Die Lungenbeteiligung bei SSc in Form von interstitieller Lungenerkrankung (ILD) und pulmonal-arterieller Hypertonie (PAH) ist eine der häufigsten Manifestationen der Erkrankung. Das Ziel dieser Arbeit besteht darin, einen Überblick über die Formen des Lungenbefalls bei SSc mit besonderem Augenmerk auf die interstitiellen Lungenerkrankungen zu geben – unter Berücksichtigung der bisher identifizierten pathogenetischen Mechanismen und der Therapieoptionen.

Abstract

Scleroderma is a generic term for autoimmunological diseases having thickened sclerotic skin lesions in common. Scleroderma belongs to a group of connective tissue diseases. The systemic form of scleroderma is called progressive systemic sclerosis (PSS) or systemic sclerosis (SSc). Lung impairments, namely interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH), are one of the most common manifestations in SSc. This article summarises the forms of lung impairment in SSc with special emphasis on interstitial lung diseases and draws attention to the so far identified pathogenetic mechanisms and the presently accepted therapeutic options.

Full Text

References

Literatur

1 Lorenz J. Pneumologie. Stuttgart; Thieme Verlag 2004: 379-381
2 Gintrac M. Note sur la sclerodermie. Rev Med Chir Paris. 1847; 2 263-281
3 LeRoy E C, Black C, Fleischmajer R. et al . Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15 202-205
4 LeRoy E C, Medsger Jr T A. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001; 28 1573-1576
5 Johnson S R, Feldman B M, Hawker G A. Classification criteria for systemic sclerosis subsets. J Rheumatol. 2007; 34 1855-1863
6 Black C M. The Aetiopathogenesis Of Systemic Sclerosis: Thick Skin – Thin Hypotheses. The Parkes Weber Lecture 1994. JR Coll Physicians London. 1995; 29 119-130
7 Arbeitsgemeinschaft dermatologische Forschung . Klinik der progressiven systemischen Sklerodermie (PSS). Hautarzt. 1986; 37 320-324
8 Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee . Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980; 23 581-590
9 Benan M, Hande I, Gul O. The natural course of progressive systemic sclerosis patients with interstitial lung involvement. Clin Rheumatol. 2007; 26 349-354
10 Clements P, Lachenbruch P, Seibold J R. et al . Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995; 22 1281-1285
11 Verrecchia F, Laboureau J, Verola O. et al . Skin involvement in scleroderma – where histological and clinical scores meet. Rheumatology. 2007; 46 833-841
12 Rodnan G P, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum. 1979; 22 130-140
13 Czirjak L, Nagy Z, Aringer M. et al . The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis. 2007; 66 966-969
14 Steen V D, Oddis C V, Conte C G. et al . Incidence of systemic sclerosis in allegheny county, Pennsylvania: A twenty-year study of hospital-diagnosed cases, 1963 – 1982. Arthritis & Rheum. 1997; 40 441-445
15 Mayes M D. Scleroderma epidemiology [review]. Rheum Dis Clin North Am. 2003; 29 239-254
16 Vonk M C, Broers B, Heijdra Y F. et al . Systemic sclerosis and its pulmonary complications in the Netherlands an epidemiological study. Ann Rheum Dis. 2009; 68 961-965
17 Mayes M D, Lacey Jr J V, Beebe-Dimmer J. et al . Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003; 48 2246-2255
18 Walker U A, Tyndall A, Czirjak L. et al . Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2007; 66 754-763
19 Hunzelmann N, Genth E, Krieg T. et al . The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford). 2008; 47 1185-1192
20 Arnett F C, Cho M, Chatterjee S. et al . Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum. 2001; 44 1359-1362
21 Shahin A A. Pulmonary involvement in systemic sclerosis. Treat Respir Med. 2006; 5 429-436
22 Pontifex E K, Hill C L, Roberts-Thomsen P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis. 2007; 66 551-553
23 Steen V D, Costantino J P, Shapiro A P. et al . Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990; 113 352-357
24 Steen V D, Medsger T A. Changes in causes of death in systemic sclerosis, 1972 – 2002. Ann Rheum Dis. 2007; 66 940-944
25 Steen V D, Lucas M, Fertig N. et al . Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol. 2007; 34 2230-2235
26 Ferri C, Valentini G, Cozzi F. et al . Systemic sclerosis study group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serological features and survival in 1012 Italian patients. Medicine. 2002; 81 139
27 Silver R M, Clements P J. Interstitial lung disease in systemic sclerosis: optimizing evaluation and management. Scleroderma Care Research. 2003; 1 3-11
28 D’Angelo W A, Fries J F, Masi A T. et al . Pathological observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969; 46 428-440
29 Weaver A L, Divertie M B, Titus J L. Pulmonary scleroderma. Dis Chest. 1968; 54 490-498
30 McNearney T A, Reveille J D, Fischbach M. et al . Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis & Rheumatism. 2007; 57 318-326
31 Mouthon L, Bérézne A, Brauner M. et al . [Interstitial lung disease in systemic sclerosis]. Rev Mal Respir. 2007; 24 1035-1046
32 Hansell D M, Kerr I A. The role of high resolution computed tomography in the diagnosis of interstitial lung disease. Thorax. 1991; 46 77-84
33 Desai S R, Veeraraghavan S, Hansell D M. et al . CT features of lung disease in systemic sclerosis: comparison with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. Radiology. 2004; 232 560-567
34 Camiciottoli G, Orlandi I, Bartolucci M. et al . Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life. Chest. 2007; 131 672-681
35 Bellia M, Cannizzaro F, Scichilone N. et al . HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities. Radiol Med. 2009; 114 190-203
36 Clements P J, Goldin J G, Kleerup E C. et al . Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis & Rheum. 2004; 50 1909-1917
37 Steen V D, Conte C, Owens G R. et al . Severe restrictive lung disease in systemic sclerosis. Arthritis & Rheum. 1994; 37 1283-1289
38 Marcisz C E, Kucharz J, Brzezinska-Wcislo L. et al . Pulmonary functional abnormalities in asymptomatic patients with systemic sclerosis. Eur J Intern Med. 2003; 14 162-165
39 Buch M H, Denton C P, Furst D E. et al . Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis. 2007; 66 169-173
40 Garin M C, Highland K B, Silver R M. et al . Limitations of the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol. 2009; 36 330-336
41 Ooi G C, Mok M Y, Tsang K W. et al . Interstitial lung disease in systemic sclerosis. An HRCT-clinical correlative study. Acta Radiologica. 2003; 44 258-264
42 Goh N S, Desai S R, Veeraraghavan S. et al . Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008; 177 1248-1254
43 Ravini M, Ferraro G, Barbieri B. et al . Changing strategies of lung biopsies in diffuse lung diseases: the impact of video-assisted thoracoscopy. Eur Respir J. 1998; 11 99-103
44 Badesch D B, Abman S H, Simmoneau G. et al . Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007; 131 1917-1928
45 Hachulla E, Carpentier P, Gressin V. et al . Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology (Oxford). 2009; 48 304-208
46 American Thoracic Society/European Respiratory Society . American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Resp Crit Care Med. 2002; 165 277-304
47 Bradley B, Branley H M, Egan J J. et al . Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008; 63 (Suppl. 5) v1-58
48 Katzenstein A L, Fiorelli R F. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol. 1995; 18 136-147
49 Kim D S, Yoo B, Lee J S. et al . The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2002; 19 121-127
50 Bouros D, Wells A U, Nicholson A G. et al . Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002; 165 1581-1586
51 deCarvalho E F, Parra E R, deSouza R. et al . Arterial and interstitial remodelling processes in non-specific interstitial pneumonia: systemic sclerosis versus idiopathic. Histopathology. 2008; 53 193-204
52 Marie I, Dominique S, Levesque H. et al . Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum. 2001; 45 346-354
53 Marie I, Ducrotte P, Denis P. et al . Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006; 24 1593-1601
54 Savarino E, Bazzica M, Zentilin P. et al . Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med. 2009; 179 408-413
55 Jain R, Shaul P W, Borok Z. et al . Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor mediated production of TGF-beta 1. Am J Respir Cell Mol Biol. 2007; 37 38-47
56 Hagimoto N, Kuwano K, Nomoto Y. et al . Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol. 1997; 16 91-101
57 Hoyles R K, Khan K, Shiwen X. et al . Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis Rheum. 2008; 58 1175-1188
58 Sonnylal S, Denton C P, Zheng B. et al . Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum. 2007; 56 334-344
59 Corrin B, Butcher D, McAnulty B J. et al . Immunohistochemical localization of TGF-β1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology. 1994; 24 145-150
60 Branley H M, du Bois R M, Wells A U. et al . PET scanning of macrophages in patients with scleroderma fibrosing alveolitis. Nucl Med Biol. 2008; 35 901-909
61 Gourh P, Tan F K, Assassi S. et al . Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum. 2006; 54 3945-3953
62 Mattuzzi S, Barbi S, Carletto A. et al . Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. J Rheumatol. 2007; 34 997-1004
63 Fonseca C, Lindahl G E, Ponticos M. et al . A polymorphism in the CTGF promotor region associated with systemic sclerosis. N Engl J Med. 2007; 357 1210-1220
64 Ates O, Müsellim B, Ongen G. et al . NRAMP1 (SLC11A1): A plausible candidate gene for systemic sclerosis (SSc) with interstitial lung involvement. J Clin Immunol. 2008; 28 73-77
65 Sumita Y, Sugiura T, Kawaguchi Y. et al . Genetic polymorphisms in the surfactant proteins in systemic sclerosis in Japanese: T/T genotype at 1580 C/T (Thr131Ile) in the SP-B gene reduces the risk of interstitial lung disease. Rheumatology (Oxford). 2008; 47 289-291
66 Dieudé P, Guedj W, Wipff J. et al . Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum. 2009; 60 225-233
67 Renzoni E, Lympany P, Sestini P. et al . Distribution of novel polymorphisms of the interleukin-8 and cxc receptor 1 und 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis & Rheumatism. 2000; 43 1633-1640
68 Ates O, Müsellim B, Ongen G. et al . Association between interleukin 10 gene (IL10) polymorphisms and systemic sclerosis with interstitial lung involvement. Rheumatol Int. 2008; 28 1123-1126
69 Bredemeier M, Chies J A, Wieck A. et al . TCRBV20S1 and TCRBV3S1 Gene Segment Polymorphisms in Systemic Sclerosis. J Rheumatol. 2008; 35 1058-1063
70 Goh N S, Veeraraghavan S, Desai S R. et al . Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum. 2007; 56 2005-2012
71 Martinez J A, Nishimura C, Guatura S B. et al . Elevation of soluble interleukin-2 receptor levels in the bronchoalveolar lavage from patients with systemic sclerosis. Rheumatol Int. 2001; 21 122-126
72 Andersen G N, Nilsson K, Pourazar J. et al . Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis. Respir Med. 2007; 101 2199-2206
73 Scheja A, Larsen K, Todorova L. et al . BALF-derived fibroblasts differ from biopsy-derived fibroblasts in systemic sclerosis. Eur Respir J. 2007; 29 446-452
74 Strange C, Bolster M B, Roth M D. et al . Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008; 177 91-98
75 Steen V D. The many faces of scleroderma. Rheum Dis Clin North Am. 2008; 34 1-15; v.
76 Kuwana M, Medsger Jr T A, Wright T M. T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors. J Clin Invest. 1995; 96 586-596
77 Ioannidis J P, Vlachoyiannopoulos P G, Haidich A B. et al . Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med. 2005; 118 2-10
78 Hu P Q, Hurwitz A A, Oppenheim J J. Immunization with DNA topoisomerase I induces autoimmune responses but not scleroderma-like pathologies in mice. J Rheumatol. 2007; 34 2243-2252
79 Takahashi H, Kuroki Y, Tanaka H. et al . Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with systemic sclerosis. Am J Respir Crit Care Med. 2000; 162 258-263
80 Yanaba K, Hasegawa M, Hamaguchi Y. et al . Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin Exp Rheumatol. 2003; 21 429-436
81 Kumánovics G, Minier T, Radics J. et al . Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol. 2008; 26 414-420
82 Hara T, Ogawa F, Yanaba K. et al . Elevated serum concentrations of polymorphonuclear neutrophilic leukocyte elastase in systemic sclerosis: association with pulmonary fibrosis. J Rheumatol. 2009; 36 99-105
83 Nomura S, Inami N, Ozaki Y. et al . Significance of microparticles in progressive systemic sclerosis with interstitial pneumonia. Platelets. 2008; 19 192-198
84 Malerba M, Radaeli A, Ragnoli B. et al . Exhaled nitric oxide levels in systemic sclerosis with and without pulmonary involvement. Chest. 2007; 132 575-580
85 Tiev K P, Cabane J, Aubourg F. et al . Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide. Eur Respir J. 2007; 30 26-30
86 Tashkin D P, Elashoff R, Clements P J. et al . Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006; 354 2655-2666
87 Tashkin D P, Elashoff R, Clements P J. et al . Effects of 1-year treatment with cyclophosphamid on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007; 176 1026-1034
88 Tzelepis G E, Plastiras S C, Karadimitrakis S P. et al . Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease. Clin Exp Rheumatol. 2007; 25 734-739
89 Hoyles R K, Ross W E, Wellsbury J. et al . A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous Cyclophosphamide followed by oral Azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis & Rheumatism. 2006; 54 3962-3970
90 Bérézne A, Ranque B, Valeyre D. et al . Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol. 2008; 35 1064-1072
91 Dheda K, Lalloo U G, Casim B. et al . Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol. 2004; 23 306-309
92 Sabnani I, Zucker M J, Rosenstein E D. et al . A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamid. Rheumatology (Oxford). 2009; 48 49-52
93 Paniagua R T, Sharpe O, Ho P P. et al . Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest. 2006; 116 2633-2642
94 Baroni S S, Santillo M, Bevilacqua F. et al . Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006; 354 2667-2676
95 Kallenberg C G, Jansen H M, Elema J D. et al . Steroid-responsive interstitial pulmonary disease in systemic sclerosis. Monitoring by bronchoalveolar lavage. Chest. 1984; 86 489-492
96 Krishna Sumanth M, Sharma V K, Khaitan B K. et al . Evaluation of oral methotrexate in the treatment of systemic sclerosis. International Journal of Dermatology. 2007; 46 218-223
97 Imokawa S, Colby T, Leslie K O. et al . Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000; 15 373-381
98 Au K, Khanna D, Clements P J. et al . Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep. 2009; 11 111-119
99 Nash R A, McSweeney P A, Crofford L J. et al . High-dose immunosuppressive therapy (HDIT) and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood. 2007; 110 1388-1396
100 Shiratsuchi M, Motomura S, Abe Y. et al . Long-term follow-up after nonmyeloablative allogeneic hematopoietic stem cell transplantation for systemic sclerosis. Clin Rheumatol. 2008; 27 1207-1209
101 Williams T J, Wilson J W. Challenges in pulmonary fibrosis: 7-novel therapies and lung transplantation. Thorax. 2008; 63 277-284
102 Schachna L, Medsger Jr T A, Dauber J H. et al . Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2006; 54 3954-3961
103 Galiè N, Torbicki A, Barst R. et al . Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004; 25 2243-2278
104 Olschewski H, Hoeper M M, Borst M M. et al . [Diagnosis and therapy of chronic pulmonary hypertension]. Pneumologie. 2006; 60 749-771
105 Hachulla E, Gressin V, Guillevin . et al . Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005; 52 3792-3800
106 Murakoshi N, Miyauchi T, Kakinuma Y. et al . Vascular endothelin-B receptor system in vivo plays a favourable inhibitory role in vascular remodeling after injury revealed by endothelin-B receptor-knockout mice. Circulation. 2002; 106 1991-1998
107 Kulasekaren P, Scavone C A, Rogers D S. et al . Endothelin-1 and TGF-{beta} independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol. 2009; (im Druck)
108 King Jr T E, Behr J, Brown K K. et al . BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008; 177 75-81
109 Seibold J R, Black C M, Denton C P. et al . Bosentan versus placebo in interstitial lung disease secondary to systemic sclerosis (SSc): the BUILD-2 Study [abstract]. Proc Am Thorac Soc. 2006; 3 A243
110 D’Alonzo G E, Barst R J, Ayres S M. et al . Survival in patients with primary pulmonary hypertension. Results form a national prospective registry. Ann Intern Med. 1991; 115 343-349
111 Rubin L J, Badesch D B, Barst R J. et al . Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346 896-903
112 McLaughlin V V. Survival in patients with pulmonary hypertension treated with first-line bosentan. Eur J Clin Invest. 2006; 36 (Suppl. 3) 10-15
113 Barst R J, Langleben D, Badesch D. et al . Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006; 47 2049-2056
114 Girgis R E, Frost A E, Hill N S. et al . Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis. 2007; 66 1467-1472
115 Benza R L, Barst R J, Galié N. et al . Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest. 2008; 134 775-782
116 Galiè N, Olschewski H, Oudiz R J. et al . Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117 3010-3019
117 Badesch D B, Hill N S, Burgess G. et al . Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007; 34 2417-2422
118 Galiè N, Rubin L J, Hoeper M M. et al . Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008; 371 2093-2100
119 Olschewski H, Simonneau G, Galie N. et al . Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347 322-329
120 Hoeper M M, Markevych I, Spiekerkoetter E. et al . Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J. 2005; 26 858-863
121 Porhownik N R, Al-Sharif H, Bshouty Z. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy. Can Respir J. 2008; 15 427-430
122 Dimitroulas T, Giannakoulas G, Karvounis H. et al . N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clin Rheumatol. 2008; 27 655-658
123 Trad S, Amoura Z, Beigelman C. et al . Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum. 2006; 54 184-191
124 Mathai S C, Hummers L K, Champion H C. et al . Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum. 2009; 60 569-577
125 Girgis R E, Mathai S C, Krishnan J A. et al . Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant. 2005; 24 1626-1631
126 Huez S, Roufosse F, Vachiéry J-L. et al . Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension?. Eur Respir J. 2007; 30 928-936
127 Steen V D, Chou M, Shanmugam V. et al . Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest. 2008; 134 146-151
128 Hanitsch L G, Burmester G-R, Witt C. et al . Skin sclerosis is only of limited value to identify SSc patients with severe manifestations – an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. Rheumatology (Oxford). 2009; 48 70-73
129 Denton C P, Merkel P A, Furst D E. et al . Recombinant human anti-transforming growth factor beta1 antibody in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 2007; 56 323-333
130 Hancock A, Armstrong L, Gama R. et al . Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol. 1998; 18 60-65
131 Granel B, Allanore Y, Chevillard C. et al . IL13RA2 gene polymorphisms are associated with systemic sclerosis. J Rheumatol. 2006; 33 2015-2019

Dr. Heiko Knoop

Medizinische Klinik III – Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin
Berufsgenossenschaftliche Universitätsklinik Bergmannsheil GmbH
Klinikum der Ruhr-Universität Bochum

Bürkle-de-la-Camp-Platz 1
44789 Bochum

Email: Heiko.Knoop@ruhr-uni-bochum.de